Matthew Goddeeris - Eloxx Pharmaceuticals VP Research
| ELOXDelisted Stock | USD 6.12 0.30 4.67% |
Insider
Matthew Goddeeris is VP Research of Eloxx Pharmaceuticals
| Phone | 781 577 5300 |
| Web | https://www.eloxxpharma.com |
Eloxx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7318) % which means that it has lost $0.7318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1523) %, meaning that it created substantial loss on money invested by shareholders. Eloxx Pharmaceuticals' management efficiency ratios could be used to measure how well Eloxx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eloxx Pharmaceuticals currently holds 13.38 M in liabilities. Eloxx Pharmaceuticals has a current ratio of 1.59, which is within standard range for the sector. Debt can assist Eloxx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eloxx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eloxx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eloxx to invest in growth at high rates of return. When we think about Eloxx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Immix Biopharma | 49 | |
| Nandan BS | Immix Biopharma | 62 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Robert McRae | Palisade Bio | N/A | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Joseph Ferra | Elevation Oncology | 49 | |
| JD MBA | Immix Biopharma | N/A | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Professor MD | Allarity Therapeutics | 67 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Ronald Dundore | Windtree Therapeutics | 69 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
Management Performance
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 |
Eloxx Pharmaceuticals Leadership Team
Elected by the shareholders, the Eloxx Pharmaceuticals' board of directors comprises two types of representatives: Eloxx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eloxx. The board's role is to monitor Eloxx Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eloxx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eloxx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vijay MBBS, Head RD | ||
| Barbara Ryan, Investor Officer | ||
| Ali MD, Chief Officer | ||
| MBA MBA, Principal CFO | ||
| Matthew Goddeeris, VP Research | ||
| Sumit MBA, CEO Pres |
Eloxx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eloxx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 30.28 M | ||||
| Shares Outstanding | 2.75 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 37.06 % | ||||
| Number Of Shares Shorted | 21.48 K | ||||
| Price To Earning | (7.94) X | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (34.42 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world |